| News

Tackling the healthcare innovation chasm

13.05.2019

The diagnosis couldn’t be worse. Healthcare innovation as we know it is stagnating and there is no cure in sight. Is that really the case? The future of healthcare innovation was the central topic at the DayOne Experts Event on May 7 in Basel. Peter Groenen, long standing industry expert, head of Translational Science at Idorsia and founding member of the DayOne Initiative, set out the facts and figures: the percentage of drug approvals is stagnating at best (except for orphan indications), the numbers of drugs brought to the patients per billion dollars spent are in stark decline, and return on investment is projected to hit the zero mark in 2020. Even when these doom figures may not become reality in the next 10 years, pharmaceutical innovation and change of the business model is required.

So, what now? Someone who knows how to cope with innovation and no financial return on investment is Melissa Penny, professor at the Swiss TPH. She shared her insights on finding therapies for neglected diseases, which are often non-profitable. Her approach is to ensure evidence of a new therapeutic or cure for those diseases is “profitable” from a global health perspective. By utilising modelling and simulating as well as data analytics the effectiveness of an intervention throughout the whole value chain can be demonstrated to support payers to make the best decision possible.

The next speeches showcased ideas on how the healthcare innovation landscape could, should and most likely will change in the years to come.

Noé Brasier from the University Hospital Basel presented the new Innovation Lab that allows testing of novel digital solutions in a sandboxed environment, enabling medical doctors to achieve a more creative and entrepreneurial approaches alongside their daily routine. Another hands-on approach was introduced by Giovanni Nisato, founding member of the Health Hacking Lab in Basel, where a growing number of enthusiastic volunteers gather to fix real world patients’ challenges.

Tackling the healthcare innovation chasm at its very root is the mission pursued by Martin Etzrodt from Akasha foundation. His big idea is to rethink science by changing the way knowledge is produced, through a decentralized platform incentivising sharing and collaboration. Last but not least, we heard from Paul Kohlhaas, founder CEO of the blockchain development company Linum Labs. Paul presented the company’s core product, Molecule, which provides an open platform for the distribution of pharmaceutical intellectual property(IP). Molecule aims to promote open source mechanisms in drug development, enabling the distribution of cost, risk and ownership. Too ambitious a vision? Check out the alpha version promised for Q3 2019!

Here are my takeaways from the panel discussions with all the speakers and participation from the audience:

1) Incentivise disruption: innovation is surely driven by science and technology. Nevertheless, making innovation happen requires the right mindset. This is especially true in the healthcare industry as regulation is high and the appetite to disrupt is low. Therefore, it is likely that innovation will not happen within the present ecosystem and finding ways to remove the entry barriers for new ideas by incentivising their adaption will be crucial for reinventing healthcare innovation.

2) Embrace complexity: most scientific research is not reproducible and is therefore wasted. The reason for “fake science” lies mostly in the growing complexity of the subject matter as we move on to understand it in greater depth. While the reductionist approach leads to “fake science”, adapting to complexity requires new ways of producing and contesting knowledge, more likely to be achieved in decentralized and non-hierarchical structures.

3) New kids on the block: innovation succeeds in cycles and generally starts and ends within a generation of researchers and managers. Firstly, breakthrough technology opens new fields, then mere incremental innovation improves the existing offerings, and at the end of the cycle, efficiency gains have to squeeze out the last drops. At the same time, new kids on the block are emerging, providing new approaches and challenging the status quo. Facilitating exchanges and a handover between the two generations by connecting experienced wisdom and creative naivety will be the magic mix to make ecosystem innovation happen.

A huge thank you to all the speakers for contributing and sharing your insights!

Peter Groenen, Idorsia

Melissa Penny, Swiss TPH

Noé Brasier, University Hospital Basel

Giovanni Nisato, Health Hacking Lab

Martin Etzrodt, Akasha Foundation

Paul Kohlhaas, Linumlabs, Founder of Molecule

Slides presented at the Event

Presentation slides by Peter Groenen, Idorsia

Presentation by Melissa Penny, Swiss TPH – The global health perspective (innovation for neglected diseases)

Presentation by Noé Brasier, University Hospital Basel – Presentation by Innovation at the hospital – The USB way to do it

Presentation by Giovanni Nisato, Health Hacking Lab

Presentation by Martin Etzrodt, Akasha Foundation – Collaborative Research

Presentation by Paul Kohlhaas, Linumlabs, Founder of Molecule – The next evolution of drug development

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
Basel Area Business & Innovation, Innovation

docdok.health involved in coronavirus research project

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

Read More
Basel Area Business & Innovation, Innovation

Celonic agrees cooperation to combat coronavirus

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

Read More
Basel Area Business & Innovation, Innovation, Invest

Idorsia receives payment of 45 million US dollars

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..

Read More
Basel Area Business & Innovation, Innovation

Humard robot disinfects using UV light

Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.

Read More
Basel Area Business & Innovation, Innovation, Invest

Roche authorized to distribute coronavirus antibody tests

Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.

Read More
Basel Area Business & Innovation, Invest

Basel is the most popular Swiss location for headquarters

Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Healthtech sector growing rapidly in the Basel Area

The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.

Read More
Basel Area Business & Innovation, Innovation, Invest

Support program has roots in Basel

The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.

Read More
Basel Area Business & Innovation, Innovation

University Hospital Basel treats coronavirus patients with plasma

The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.